Safety and efficacy of sargramostim (GM‐CSF) in the treatment of Alzheimer's disease

INTRODUCTION: Inflammatory markers have long been observed in the brain, cerebrospinal fluid (CSF), and plasma of Alzheimer's disease (AD) patients, suggesting that inflammation contributes to AD and might be a therapeutic target. However, non‐steroidal anti‐inflammatory drug trials in AD and m...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Alzheimers Dement (N Y)
Glavni autori: Potter, Huntington, Woodcock, Jonathan H., Boyd, Timothy D., Coughlan, Christina M., O'Shaughnessy, John R., Borges, Manuel T., Thaker, Ashesh A., Raj, Balaibail A., Adamszuk, Katarzyna, Scott, David, Adame, Vanesa, Anton, Paige, Chial, Heidi J., Gray, Helen, Daniels, Joseph, Stocker, Michelle E., Sillau, Stefan H.
Format: Artigo
Jezik:Inglês
Izdano: John Wiley and Sons Inc. 2021
Teme:
Research Articles
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7988877/
https://ncbi.nlm.nih.gov/pubmed/33778150
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/trc2.12158
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items